Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 8:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 132 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: rt-PA Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis

NCT02315898
View directory record Official record
Conditions
Plastic Bronchitis, Protein-Losing Enteropathies, Healthy
Interventions
Treatment-inhaled tPA
Drug
Lead sponsor
University of Michigan
Other
Eligibility
5 Years to 24 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
6
States / cities
Palo Alto, California • Chicago, Illinois • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 24, 2026, 8:37 PM EDT
Completed Phase 1Phase 2 Interventional

In Vivo Angiostatin Generation Using Tissue Plasminogen Activator and Captopril in Treating Patients With Progressive Metastatic Cancer

NCT00086723
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
recombinant tissue plasminogen activator, captopril
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 24, 2026, 8:37 PM EDT
Completed No phase listed Observational

Early Mobilization of Ischemic Stroke Patients Within 24-hours After Intravenous-Tissue Plasminogen Activator (IV-tPA)

NCT01331200
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 27, 2013 · Synced Oct 24, 2026, 8:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

NCT01413542
View directory record Official record
Conditions
Hypertension, Diabetes Type 2
Interventions
Sitagliptin (DPP4 inhibitor), Substance P,, bradykinin, enalaprilat (ACE inhibitor), Glucagon-like peptide 1, brain natriuretic peptide
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 24, 2026, 8:37 PM EDT
Completed Phase 2 Interventional Results available

Clinical Trial on Treatment of Intraventricular Hemorrhage

NCT00650858
View directory record Official record
Conditions
Intraventricular Hemorrhage
Interventions
tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 24, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Results available

tPA by Endovascular Administration for the Treatment of Submassive PE Using CDT for the Reduction of Thrombus Burden

NCT04248868
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
The Bashir™ Endovascular Catheter, r-tPA
Device · Drug
Lead sponsor
Thrombolex, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • Miami, Florida • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 24, 2026, 8:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Thrombolytic Care During Inter-hospital Transfer

NCT02752256
View directory record Official record
Conditions
Stroke
Interventions
Tissue Plasminogen Activator
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 24, 2026, 8:37 PM EDT
Withdrawn Phase 1 Interventional

Study for the Use of Alteplase in Patients Who Awaken With Stroke

NCT01150266
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Alteplase (tPA)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 24, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Results available

Tenecteplase in Stroke Patients Between 4.5 and 24 Hours

NCT03785678
View directory record Official record
Conditions
THROMBOLYSIS
Interventions
Tenecteplase, Placebo
Biological · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
94
States / cities
Birmingham, Alabama • Mesa, Arizona • Anaheim, California + 74 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 24, 2026, 8:37 PM EDT
Recruiting Not applicable Interventional

Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe

NCT05983757
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Experimental: endovascular thrombectomy in patients who suffer a distal medium vessel occlusion, Standard medical management
Device · Other
Lead sponsor
Raul Nogueira
Other
Eligibility
18 Years and older
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Iowa City, Iowa • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 24, 2026, 8:37 PM EDT
Suspended No phase listed Observational

Augmented Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for PE

NCT06310018
View directory record Official record
Conditions
Pulmonary Embolism, Right Ventricular Dysfunction, Right Ventricular Failure
Interventions
Ultrasound-facilitated, catheter-directed lower-dose fibrinolysis, Tissue Plasminogen Activator
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 24, 2026, 8:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion

NCT01222117
View directory record Official record
Conditions
Acute Peripheral Arterial Occlusion
Interventions
Plasmin, Plasminogen Activator, Placebo
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Buffalo, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 24, 2026, 8:37 PM EDT
Terminated Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke

NCT02072226
View directory record Official record
Conditions
Stroke
Interventions
Alteplase, Alteplase Placebo, Aspirin, Aspirin Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 24, 2026, 8:37 PM EDT
Completed No phase listed Observational

New York City Mobile Interventional Stroke Team

NCT03048292
View directory record Official record
Conditions
Acute Stroke
Interventions
Acute Endovascular Stroke Treatment
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 24, 2026, 8:37 PM EDT
Recruiting Phase 2 Interventional

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

NCT06392295
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Hormone Sensitive Prostate Cancer
Interventions
Para Aortic Radiation Therapy: Photon Therapy, Para Aortic Radiation Therapy: Proton Therapy, Androgen Deprivation Therapy, Androgen Receptor Signaling Inhibitor
Radiation · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 24, 2026, 8:37 PM EDT
Recruiting Not applicable Interventional

Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

NCT06423963
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Physical Activity, Nutrition Counseling, Resistance Training
Behavioral
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 8:37 PM EDT
Completed Phase 2 Interventional Results available

Tenecteplase in Patients With COVID-19

NCT04505592
View directory record Official record
Conditions
COVID-19, Respiratory Failure, ARDS
Interventions
Tenecteplase, Placebo
Drug
Lead sponsor
Hooman Poor
Other
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 24, 2026, 8:37 PM EDT
Completed Phase 2 Interventional Results available

Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00066222
View directory record Official record
Conditions
Lung Cancer
Interventions
Cisplatin, Etoposide, Radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
104
States / cities
Birmingham, Alabama • Castro Valley, California • Hayward, California + 74 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 24, 2026, 8:37 PM EDT
Active, not recruiting Phase 2 Interventional

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

NCT02923778
View directory record Official record
Conditions
Leiomyosarcoma, Liposarcoma, Sarcoma G2, Sarcoma G3, Soft Tissue Sarcoma, Soft Tissue Sarcoma of the Trunk and Extremities, Stage I Soft Tissue Sarcoma AJCC v7, Stage II Soft Tissue Sarcoma AJCC v7, Undifferentiated Pleomorphic Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Talimogene Laherparepvec
Procedure · Radiation · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
16
States / cities
Phoenix, Arizona • Duarte, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 8:37 PM EDT
Completed Not applicable Interventional Results available

Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial

NCT01657461
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Intravenous (IV) recombinant human tissue plasminogen activator (rtPA), Solitaire revascularization device
Drug · Device
Lead sponsor
Medtronic Neurovascular Clinical Affairs
Industry
Eligibility
18 Years to 80 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 24, 2026, 8:37 PM EDT
Completed Phase 1Phase 2 Interventional

Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial

NCT00250991
View directory record Official record
Conditions
Stroke
Interventions
activase, integrilin
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
19
States / cities
Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 8, 2009 · Synced Oct 24, 2026, 8:37 PM EDT
Completed Phase 3 Interventional Results available

Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis

NCT00790335
View directory record Official record
Conditions
Deep Vein Thrombosis, Venous Thrombosis, Postphlebitic Syndrome, Venous Thromboembolism, Post Thrombotic Syndrome
Interventions
Recombinant tissue plasminogen activator (rt-PA)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
16 Years to 75 Years
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
56
States / cities
Glendale, Arizona • Orange, California • Stanford, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 24, 2026, 8:37 PM EDT
Terminated No phase listed Observational

Improving Patient Access to Stroke Therapy Study

NCT01870492
View directory record Official record
Conditions
Ischemic Stroke, Transient Ischemic Attack
Interventions
Activase, Endovascular therapy
Drug · Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 24, 2026, 8:37 PM EDT
Completed Phase 2 Interventional

Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke

NCT02448069
View directory record Official record
Conditions
Stroke, Cerebral Ischemia
Interventions
Argatroban
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 24, 2026, 8:37 PM EDT